Balaji Amines Ltd Share Price – NSE /  BSE

Chemicals, Small Cap

Profit before tax slipped 41.81% year on year to Rs 40.89 crore in the quarter ended 31 December 2024.

EBITDA for Q3 FY25 stood at Rs 54 crore, down 34.94%, compared to Rs 83 crore in Q3 FY24. EBITDA margin for Q3 FY25 was reduced to 17% in Q3 FY25 as against 21% reported in the same period a year ago.

Total expense declined 13.02% YoY to Rs 279.70 crore during the quarter. Cost of raw material consumed stood at Rs 168.50 crore (down 16.29% YoY), while employee benefits expenses were at Rs 18.53 crore (down 9.83% YoY) in Q3 FY25.

The company’s revenue from the amines & specialty chemicals business stood at Rs 310.35 crore (down 19.04% YoY), while income from the hotel division was at Rs 9.68 crore (up 21.91% YoY) during the period under review.

During the quarter, amines volumes stood at 7,515 MT; amines derivatives volumes stood at 8,809 MT, and specialty chemicals volumes stood at 7,773 MT.

On a standalone basis, the company’s net profit declined 14.1% to Rs 35.69 crore in Q3 FY25 as against Rs 41.55 crore posted in Q3 FY24. Revenue from operations was at Rs 299.23 crore in Q3 FY25, down 2.79% YoY.

Meanwhile, the company has installed rooftop solar plants at various locations, and the Maharashtra State Electricity Distribution Company (MSEDCL) has approved these installations. The capacities of these solar units for captive consumption are 2.655 MW, and the expected unit generated is approximately 12 lakh units.

D. Ram Reddy, MD, Balaji Amines, said, “During Q3 FY25, our financial and business performance remained stable despite the challenges posed by global macroeconomic conditions. However, as volume uptake gradually increases, EBITDA and PAT margins are expected to improve in line with industry recovery.

The resurgence in domestic demand, along with positive trends in international markets, is driving this momentum. Additionally, the utilization of expanded capacities will contribute to margin enhancement as some of our products progress through the final approval stages with end-user industries.

This progress is further supported by our ongoing investments in key projects, reinforcing our commitment to operational excellence. Electronic Grade DMC, Propylene Glycol Pharma Grade, and Dimethyl Ether projects are progressing well, aligning with our strategic growth objectives. These initiatives are designed to strengthen our market presence, enhance product offerings, and meet the evolving needs of our customers.

Looking ahead, we maintain a positive outlook for long-term opportunities, anticipating growth and increased prospects during the fiscal year 2025-26. Our focus on inherent strengths and competencies positions us as a leading force in amines and specialty chemicals, guiding us through market complexities towards greater excellence.”

Balaji Amines is a leading manufacturer of aliphatic amines in India. Broadly, the company is specialized in manufacturing methyl amines, ethyl amines, derivatives of specialty chemicals, and natural products, and its business is broadly classified into three segments: amines, specialty chemicals, and derivatives.

Powered by Capital Market - Live News

Net profit of Balaji Amines declined 32.77% to Rs 33.19 crore in the quarter ended December 2024 as against Rs 49.37 crore during the previous quarter ended December 2023. Sales declined 18.42% to Rs 312.73 crore in the quarter ended December 2024 as against Rs 383.36 crore during the previous quarter ended December 2023.

Powered by Capital Market - Live News

Balaji Amines will hold a meeting of the Board of Directors of the Company on 12 February 2025.

Powered by Capital Market - Live News

Net profit of Balaji Amines declined 32.77% to Rs 33.19 crore in the quarter ended December 2024 as against Rs 49.37 crore during the previous quarter ended December 2023. Sales declined 18.42% to Rs 312.73 crore in the quarter ended December 2024 as against Rs 383.36 crore during the previous quarter ended December 2023.

Powered by Capital Market - Live News

Balaji Amines will hold a meeting of the Board of Directors of the Company on 12 February 2025.

Powered by Capital Market - Live News

Revenue from operations declined 8.85% year on year (YoY) to Rs 346.88 crore in the quarter ended 30 September 2024.

Profit before tax stood at Rs 56.81 crore in September 2024 quarter, registering a growth of 18.33% on YoY basis.

Sequentially, the company’s net profit and revenue from operations in second quarter of FY25 declined 5.34% and 9.84%, respectively.

EBITDA during the quarter stood at Rs 70 crore, down 5.41% as compared to Rs 74 crore in Q1 of FY25. EBITDA margin for Q2FY25 improved to 20% in Q2 FY25 as against 19% reported in the same period a year ago.

Total expenses declined 11.8% YoY to Rs 299.26 crore during the quarter. Cost of raw material consumed stood at Rs 221.88 crore (up 16% YoY) while other expenses were at Rs 78.92 crore (down 7.31% YoY) in Q2 FY25.

The company’s revenue from amines & specilaity chemicals business stood at Rs 348.24 crore (down 8.4% YoY) while income from hotel division was at Rs 7.26 crore (up 7.88% YoY) during the period under review.

Total volumes stood at 26,348 MT for Q2 of FY25, registering de-growth of 6.14% on a sequential basis.

During the quarter, amines volumes stood at 7,616 MT; amines derivatives volumes stood at 8,685 MT and specialty chemicals volumes stood at 10,046 MT.

Looking ahead, Balaji Amines is proposing to set up a plant for manufacture of N-(N-Butyl) Thiophosphoric Triamide (NBPT) with a capacity of 2500 TPA which will be taken up next Financial Year.

Additionally, the company aims to expand its ACN production capacity by setting up a new plant with a 60 MT/day capacity at Unit-III in MIDC, Chincholi. The discussion for transfer of the latest technology (reducing the cost of production) is under final stage and the company may sign the agreement by the end of November 2024. New equipment as per the latest technology will be integrated with the existing ACN plant at Unit-III.

In a separate development, Balaji Speciality Chemicals, a subsidiary of Balaji Amines, has planned a major expansion with an investment of approximately Rs 750 crore. This project will focus on a range of products, including Hydrogen Cyanide (HCN), Sodium Cyanide (NaCN) in both 30% solution and 100% solid forms, EDTA, EDTA-2Na, Benzyl Cyanide (BnCN), Phenylacetic Acid (PAA), and Tri Ethyl Ortho Formate (TEOF)/Tri Methyl Ortho Formate (TMOF).

D. Ram Reddy, managing director, Balaji Amines, said, “In the Q2 quarter, we reported a revenue of Rs 356 crore, achieving an EBITDA margin of 20%. This marks a 110-basis-point improvement over last quarter, reflecting our focus on higher margin products amid a challenging industry environment.

While the broader market experienced pressure in Q2, both the API and agrochemical looks promising over a long term, and we are well-positioned to seize these future opportunities. With our expanded capacities and a sharpened focus on operational efficiency, we are confident in our ability to drive sustainable growth in the coming quarters.

Our recent developments demonstrate significant progress in expanding our production capacity. With the successful commencement of Methylamines production at Unit-IV, our total annual installed capacity has increased from 48,000 MT to 88,000 MT across all three units.

Additionally, Unit-I and Unit-III have achieved BIS Certification for 'Morpholine,' strengthening our quality standards and making us the only BIS-certified Morpholine manufacturer in India. Projects in Electronic Grade DMC, Propylene Glycol Pharma Grade, and Dimethyl Ether are also advancing well, reflecting our commitment to operational excellence. As we look forward, our strong foundation in core capabilities positions us well to navigate industry dynamics and capture growth opportunities.”

Balaji Amines is a leading manufacturer of aliphatic amines in India. Broadly, the company is specialized in manufacturing methyl amines, ethyl amines, derivatives of specialty chemicals and natural product and its business is broadly classified into three segments - amines, specialty chemicals and derivatives.

Shares of Balaji Amines declined 1.92% to Rs 1,996.15 on the BSE.

Powered by Capital Market - Live News

Profit before tax slipped 41.81% year on year to Rs 40.89 crore in the quarter ended 31 December 2024.

EBITDA for Q3 FY25 stood at Rs 54 crore, down 34.94%, compared to Rs 83 crore in Q3 FY24. EBITDA margin for Q3 FY25 was reduced to 17% in Q3 FY25 as against 21% reported in the same period a year ago.

Total expense declined 13.02% YoY to Rs 279.70 crore during the quarter. Cost of raw material consumed stood at Rs 168.50 crore (down 16.29% YoY), while employee benefits expenses were at Rs 18.53 crore (down 9.83% YoY) in Q3 FY25.

The company’s revenue from the amines & specialty chemicals business stood at Rs 310.35 crore (down 19.04% YoY), while income from the hotel division was at Rs 9.68 crore (up 21.91% YoY) during the period under review.

During the quarter, amines volumes stood at 7,515 MT; amines derivatives volumes stood at 8,809 MT, and specialty chemicals volumes stood at 7,773 MT.

On a standalone basis, the company’s net profit declined 14.1% to Rs 35.69 crore in Q3 FY25 as against Rs 41.55 crore posted in Q3 FY24. Revenue from operations was at Rs 299.23 crore in Q3 FY25, down 2.79% YoY.

Meanwhile, the company has installed rooftop solar plants at various locations, and the Maharashtra State Electricity Distribution Company (MSEDCL) has approved these installations. The capacities of these solar units for captive consumption are 2.655 MW, and the expected unit generated is approximately 12 lakh units.

D. Ram Reddy, MD, Balaji Amines, said, “During Q3 FY25, our financial and business performance remained stable despite the challenges posed by global macroeconomic conditions. However, as volume uptake gradually increases, EBITDA and PAT margins are expected to improve in line with industry recovery.

The resurgence in domestic demand, along with positive trends in international markets, is driving this momentum. Additionally, the utilization of expanded capacities will contribute to margin enhancement as some of our products progress through the final approval stages with end-user industries.

This progress is further supported by our ongoing investments in key projects, reinforcing our commitment to operational excellence. Electronic Grade DMC, Propylene Glycol Pharma Grade, and Dimethyl Ether projects are progressing well, aligning with our strategic growth objectives. These initiatives are designed to strengthen our market presence, enhance product offerings, and meet the evolving needs of our customers.

Looking ahead, we maintain a positive outlook for long-term opportunities, anticipating growth and increased prospects during the fiscal year 2025-26. Our focus on inherent strengths and competencies positions us as a leading force in amines and specialty chemicals, guiding us through market complexities towards greater excellence.”

Balaji Amines is a leading manufacturer of aliphatic amines in India. Broadly, the company is specialized in manufacturing methyl amines, ethyl amines, derivatives of specialty chemicals, and natural products, and its business is broadly classified into three segments: amines, specialty chemicals, and derivatives.

Powered by Capital Market - Live News

Net profit of Balaji Amines declined 32.77% to Rs 33.19 crore in the quarter ended December 2024 as against Rs 49.37 crore during the previous quarter ended December 2023. Sales declined 18.42% to Rs 312.73 crore in the quarter ended December 2024 as against Rs 383.36 crore during the previous quarter ended December 2023.

Powered by Capital Market - Live News

Balaji Amines will hold a meeting of the Board of Directors of the Company on 12 February 2025.

Powered by Capital Market - Live News

Net profit of Balaji Amines declined 32.77% to Rs 33.19 crore in the quarter ended December 2024 as against Rs 49.37 crore during the previous quarter ended December 2023. Sales declined 18.42% to Rs 312.73 crore in the quarter ended December 2024 as against Rs 383.36 crore during the previous quarter ended December 2023.

Powered by Capital Market - Live News

Balaji Amines will hold a meeting of the Board of Directors of the Company on 12 February 2025.

Powered by Capital Market - Live News

Revenue from operations declined 8.85% year on year (YoY) to Rs 346.88 crore in the quarter ended 30 September 2024.

Profit before tax stood at Rs 56.81 crore in September 2024 quarter, registering a growth of 18.33% on YoY basis.

Sequentially, the company’s net profit and revenue from operations in second quarter of FY25 declined 5.34% and 9.84%, respectively.

EBITDA during the quarter stood at Rs 70 crore, down 5.41% as compared to Rs 74 crore in Q1 of FY25. EBITDA margin for Q2FY25 improved to 20% in Q2 FY25 as against 19% reported in the same period a year ago.

Total expenses declined 11.8% YoY to Rs 299.26 crore during the quarter. Cost of raw material consumed stood at Rs 221.88 crore (up 16% YoY) while other expenses were at Rs 78.92 crore (down 7.31% YoY) in Q2 FY25.

The company’s revenue from amines & specilaity chemicals business stood at Rs 348.24 crore (down 8.4% YoY) while income from hotel division was at Rs 7.26 crore (up 7.88% YoY) during the period under review.

Total volumes stood at 26,348 MT for Q2 of FY25, registering de-growth of 6.14% on a sequential basis.

During the quarter, amines volumes stood at 7,616 MT; amines derivatives volumes stood at 8,685 MT and specialty chemicals volumes stood at 10,046 MT.

Looking ahead, Balaji Amines is proposing to set up a plant for manufacture of N-(N-Butyl) Thiophosphoric Triamide (NBPT) with a capacity of 2500 TPA which will be taken up next Financial Year.

Additionally, the company aims to expand its ACN production capacity by setting up a new plant with a 60 MT/day capacity at Unit-III in MIDC, Chincholi. The discussion for transfer of the latest technology (reducing the cost of production) is under final stage and the company may sign the agreement by the end of November 2024. New equipment as per the latest technology will be integrated with the existing ACN plant at Unit-III.

In a separate development, Balaji Speciality Chemicals, a subsidiary of Balaji Amines, has planned a major expansion with an investment of approximately Rs 750 crore. This project will focus on a range of products, including Hydrogen Cyanide (HCN), Sodium Cyanide (NaCN) in both 30% solution and 100% solid forms, EDTA, EDTA-2Na, Benzyl Cyanide (BnCN), Phenylacetic Acid (PAA), and Tri Ethyl Ortho Formate (TEOF)/Tri Methyl Ortho Formate (TMOF).

D. Ram Reddy, managing director, Balaji Amines, said, “In the Q2 quarter, we reported a revenue of Rs 356 crore, achieving an EBITDA margin of 20%. This marks a 110-basis-point improvement over last quarter, reflecting our focus on higher margin products amid a challenging industry environment.

While the broader market experienced pressure in Q2, both the API and agrochemical looks promising over a long term, and we are well-positioned to seize these future opportunities. With our expanded capacities and a sharpened focus on operational efficiency, we are confident in our ability to drive sustainable growth in the coming quarters.

Our recent developments demonstrate significant progress in expanding our production capacity. With the successful commencement of Methylamines production at Unit-IV, our total annual installed capacity has increased from 48,000 MT to 88,000 MT across all three units.

Additionally, Unit-I and Unit-III have achieved BIS Certification for 'Morpholine,' strengthening our quality standards and making us the only BIS-certified Morpholine manufacturer in India. Projects in Electronic Grade DMC, Propylene Glycol Pharma Grade, and Dimethyl Ether are also advancing well, reflecting our commitment to operational excellence. As we look forward, our strong foundation in core capabilities positions us well to navigate industry dynamics and capture growth opportunities.”

Balaji Amines is a leading manufacturer of aliphatic amines in India. Broadly, the company is specialized in manufacturing methyl amines, ethyl amines, derivatives of specialty chemicals and natural product and its business is broadly classified into three segments - amines, specialty chemicals and derivatives.

Shares of Balaji Amines declined 1.92% to Rs 1,996.15 on the BSE.

Powered by Capital Market - Live News